Table 3.
Characteristics of Participants and Outcome of Community Evaluation of HBV Treatment Eligibility
| Characteristic | All Participants (n=94) |
HIV-Positive Populationa (n=24) |
HIV-Negative Population (n=69) |
|---|---|---|---|
| Age, y, median (IQR) | 36 (29–41) | 39 (36–47) | 34 (27–38) |
| Sex, female | 49 (52) | 14 (58) | 35 (51) |
| CD4 count, cells/mm3, median (IQR)b | 519 (412–577) | ||
| On ART | 16/24 (67) | ||
| On TDF or 3TC | 16/24 (67) | ||
| Signs of CLD | 3 (3) | 1 (4) | 2 (3) |
| Past medical history | |||
| History of tuberculosis | 7 (7) | 6 (25) | 1 (1) |
| Diabetes | 1 (1) | 0 (0) | 1 (1) |
| Renal disease | 1 (1) | 0 (0) | 1 (1) |
| Hypertension | 1 (1) | 0 (0) | 1 (1) |
| Alcohol consumption | |||
| Abstinent | 59 (63) | 12 (50) | 47 (68) |
| Low risk | 23 (25) | 9 (38) | 14 (20) |
| Hazardous | 10 (11) | 3 (13) | 6 (9) |
| Harmful | 1 (1) | 0 (0) | 1 (1) |
| Alcohol dependence | 1 (1) | 0 (0) | 1 (1) |
| Hepatitis D and C serology | |||
| Anti-HDV | 2 (2) | 0 (0) | 2 (3) |
| HCV Ag/Ab | 0 (0) | 0 (0) | 0 (0) |
| Hepatitis B viral markers | |||
| HBeAg | 10 (11) | 6 (25) | 4 (6) |
| HBV DNA, IU/mL, median (IQR) | 81 (<32–801) | <32 (<32–<32) | 215 (51–2880) |
| HBV DNA>2000 IU/mL | 19 (20) | 0 (0) | 19 (28) |
| HBV DNA>20000 IU/mL | 11 (12) | 0 (0) | 11 (16) |
| ALT, IU/L, median (IQR)c | 10 (8–13) | 12 (10–15) | 9 (8–12) |
| ALT>ULN | 2 (2) | 0 (0) | 2 (3) |
| ALT>2× ULN | 0 (0) | 0 (0) | 0 (0) |
| Liver stiffness, kPa, median (IQR) | 4.8 (4.0–6.4) | 4.5 (4.0–5.4) | 5.1 (4.0–6.9) |
| ≥7.9 kPa | 10 (11) | 1 (4) | 9 (9) |
| ≥9.5 kPa | 4 (4) | 1 (4) | 3 (4) |
Data are No. (%) except where indicated.
Abbreviations: 3TC, lamivudine; Ag/Ab, antigen/antibody; ALT, alanine transaminase; ART, antiretroviral therapy; CD4, cluster of differentiation 4; CLD, chronic liver disease; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; IQR, interquartile range; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal.
One participant did not consent to HIV testing.
CD4 count available for 21/23 (91%) of HIV-positive individuals.
The assay upper limit of normal was 32 U/L.